Publications
Detailed Information
Topical tacrolimus 0.03% for maintenance therapy in steroid-dependent, recurrent phlyctenular keratoconjunctivitis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Chang Ho | - |
dc.contributor.author | Kim, Mee Kum | - |
dc.contributor.author | Oh, Joo Youn | - |
dc.date.accessioned | 2024-05-16T01:46:42Z | - |
dc.date.available | 2024-05-16T01:46:42Z | - |
dc.date.created | 2019-05-30 | - |
dc.date.created | 2019-05-30 | - |
dc.date.created | 2019-05-30 | - |
dc.date.issued | 2018-01 | - |
dc.identifier.citation | Cornea, Vol.37 No.2, pp.168-171 | - |
dc.identifier.issn | 0277-3740 | - |
dc.identifier.uri | https://hdl.handle.net/10371/202849 | - |
dc.description.abstract | Purpose: To evaluate the efficacy of topical tacrolimus 0.03% as steroid-free maintenance therapy in young patients with severe, recurrent phlyctenular keratoconjunctivitis (PKC). Methods: The medical records of 6 eyes of 5 patients (4 children and 1 young adult) with recurrent, steroid-dependent PKC were reviewed. The patients were treated with combined application of topical steroids and tacrolimus 0.03% in the active phase and maintained on topical tacrolimus alone after remission. Results: The clinical signs, symptoms, and visual acuities resolved in all patients after 25.2 +/- 16.9 days of combined treatment with steroids and tacrolimus. After disease remission, the patients were maintained on topical tacrolimus 0.03% once daily alone for 8.4 +/- 4.7 months, and no recurrence occurred during 10.6 +/- 1.9 months of follow-up. Tacrolimus was successfully discontinued in 2 patients without further recurrence. There were no ocular side effects related to the use of topical tacrolimus. Conclusions: Topical tacrolimus 0.03% was effective in maintaining long-term remission in patients with recurrent, steroid-dependent PKC. | - |
dc.language | 영어 | - |
dc.publisher | Lippincott Williams & Wilkins Ltd. | - |
dc.title | Topical tacrolimus 0.03% for maintenance therapy in steroid-dependent, recurrent phlyctenular keratoconjunctivitis | - |
dc.type | Article | - |
dc.identifier.doi | 10.1097/ICO.0000000000001440 | - |
dc.citation.journaltitle | Cornea | - |
dc.identifier.wosid | 000429227200015 | - |
dc.identifier.scopusid | 2-s2.0-85043687113 | - |
dc.citation.endpage | 171 | - |
dc.citation.number | 2 | - |
dc.citation.startpage | 168 | - |
dc.citation.volume | 37 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Mee Kum | - |
dc.contributor.affiliatedAuthor | Oh, Joo Youn | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | VERSUS-HOST-DISEASE | - |
dc.subject.keywordPlus | EYE DISEASE | - |
dc.subject.keywordPlus | OINTMENT | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | phlyctenular keratoconjunctivitis | - |
dc.subject.keywordAuthor | steroid | - |
dc.subject.keywordAuthor | tacrolimus | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.